Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Amoxicillin. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 9/20 | 1.00 |
| ▸ | LMNA | P02545 | 4/20 | 1.00 |
| ▸ | RARB | P10826 | 1/20 | 1.00 |
| ▸ | RARG | P13631 | 1/20 | 1.00 |
| ▸ | NR1H2 | P55055 | 1/20 | 1.00 |
| ▸ | NR1H3 | Q13133 | 1/20 | 1.00 |
| ▸ | NR1I3 | Q14994 | 1/20 | 1.00 |
| ▸ | RECQL | P46063 | 4/20 | 0.84 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.84 |
| ▸ | HPGD | P15428 | 3/20 | 0.84 |
| ▸ | POLB | P06746 | 2/20 | 0.84 |
| ▸ | MEN1 | O00255 | 1/20 | 0.84 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.84 |
| ▸ | TEK | Q02763 | 1/20 | 0.84 |
| ▸ | SLC15A2 | Q16348 | 1/20 | 0.84 |
| ▸ | TSHR | P16473 | 2/20 | 0.82 |
| ▸ | CYP3A4 | P08684 | 5/20 | 0.70 |
| ▸ | GLA | P06280 | 1/20 | 0.70 |
| ▸ | BLM | P54132 | 1/20 | 0.70 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.70 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Amoxicillin SCHEMBL11378022 | 1.00 | KDM4E (1.00) | KDM4ELMNARARBRARGNR1H2 | |
| Amoxicillin SCHEMBL18872879 | 1.00 | KDM4E (1.00) | KDM4ELMNARARBRARGNR1H2 | |
| Amoxicillin SCHEMBL13662733 | 1.00 | KDM4E (1.00) | KDM4ELMNARARBRARGNR1H2 | |
| Amoxicillin SCHEMBL13105238 | 1.00 | KDM4E (1.00) | KDM4ELMNARARBRARGNR1H2 | |
| Amoxicillin SCHEMBL2636892 | 1.00 | KDM4E (1.00) | KDM4ELMNARARBRARGNR1H2 | |
| Amoxicillin SCHEMBL3427 | 1.00 | KDM4E (1.00) | KDM4ELMNARARBRARGNR1H2 | |
| Amoxicillin SCHEMBL24768939 | 1.00 | KDM4E (1.00) | KDM4ELMNARARBRARGNR1H2 | |
| Amoxicillin SCHEMBL13481266 | 1.00 | KDM4E (1.00) | KDM4ELMNARARBRARGNR1H2 | |
| Amoxicillin SCHEMBL15387744 | 1.00 | KDM4E (1.00) | KDM4ELMNARARBRARGNR1H2 | |
| Amoxicillin SCHEMBL22380860 | 1.00 | KDM4E (1.00) | KDM4ELMNARARBRARGNR1H2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1302 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260027140-A1 | COMPOSITIONS AND METHODS FOR TREATING AND AMELIORATING RESPIRATORY CONDITIONS AND INFLAMMATION OF MUCOSA | ATOPIC MEDICAL INC (US) | 2026-01-29 | — | — | US | claimed |
| US-20240390364-A1 | Novel Pyridine Compositions and their use in methods for preventing or treating diseases, disorders and conditions | REID CHRISTOPHER BRIAN (US) | 2024-11-28 | — | — | US | claimed |
| US-20240050419-A1 | COMPOSITIONS AND METHODS FOR TREATING, AMELIORATING AND PREVENTING H. PYLORI INFECTIONS | CENTRE FOR DIGESTIVE DISEASES (AU) | 2024-02-15 | — | — | US | claimed |
| US-20230414584-A1 | ADMINISTRATION OF ANTIBIOTIC COMPOUNDS FOR THE TREATMENT OF STREPTOCOCCAL INFECTIONS FOR THE TREATMENT OF PSORIASIS | CENTRE FOR DIGESTIVE DISEASES (AU) | 2023-12-28 | — | — | US | claimed |
| CN-116650492-A | Administration of antibiotic compounds for the treatment of streptococcal infections to treat psoriasis | 消化系统疾病中心 | 2023-08-29 | — | — | CN | claimed |
| EP-3955927-A1 | COMPOSITIONS AND METHODS FOR TREATING, AMELIORATING AND PREVENTING H. PYLORI INFECTIONS | Borody, Thomas Julius (AU) | 2022-02-23 | — | — | EP | claimed |
| CN-113939293-A | Compositions and methods for treating, ameliorating and preventing helicobacter pylori infection | 托马斯·朱利叶斯·波洛迪 | 2022-01-14 | — | — | CN | claimed |
| US-20210353609-A1 | COMPOSITIONS AND METHODS FOR TREATING, AMELIORATING AND PREVENTING H. PYLORI INFECTIONS | CENTRE FOR DIGESTIVE DISEASES (AU) | 2021-11-18 | — | — | US | claimed |
| US-20210077413-A1 | CHOLESTYRAMINE FORMULATIONS AND METHODS OF USE | PMSCI RESEARCH AND DEVELOPMENT INC. (CA) | 2021-03-18 | — | — | US | claimed |
| WO-2020263729-A1 | METHOD AND FORMULATION FOR TREATMENT OF WOUNDS BY NEW TISSUE REGENERATION WITH REDUCED TRAUMA AND SCAR TISSUE FORMATION | GALLINA CHARLES (US) | 2020-12-30 | — | — | WO | claimed |
| US-20100009008-A1 | BACTERIOSTATIC OR BACTERIOCIDAL COMPOSITIONS AND METHODS | REVALESIO CORPORATION (US) | 2010-01-14 | — | — | US | claimed |
| WO-2009131692-A1 | SUBSTRATES FOR DELIVERY OF PHYSIOLOGICALLY ACTIVE AGENTS | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ALABAMA (US) | 2009-10-29 | — | — | WO | claimed |
| US-20090263495-A1 | BACTERIOSTATIC OR BACTERIOCIDAL COMPOSITIONS AND METHODS | REVALESIO CORPORATION (US) | 2009-10-22 | — | — | US | claimed |
| US-20070067045-A1 | Systems and methods for skin wrinkle removal | AR2 PARTNERS, INC. | 2007-03-22 | — | — | US | claimed |
| US-20060110445-A1 | Dispersible tablet for oral administration | RANBAXY LABORATORIES LIMITED (IN) | 2006-05-25 | — | — | US | claimed |
| CN-1681497-A | Dispersible tablets for oral administration | RANBAXY LAB LTD (IN) | 2005-10-12 | — | — | CN | claimed |
| EP-1539146-A1 | DISPERSIBLE TABLETS FOR ORAL ADMINISTRATION | RANBAXY LABORATORIES, LTD. (IN) | 2005-06-15 | — | — | EP | claimed |
| WO-2004006917-A1 | DISPERSIBLE TABLETS FOR ORAL ADMINISTRATION | RANBAXY LABORATORIES LIMITED (US) | 2004-01-22 | — | — | WO | claimed |
| US-20020042394-A1 | Cobalamin compounds useful as antibiotic agents and as imaging agents | HOGENKAMP HENRICUS P C (US) | 2002-04-11 | — | — | US | claimed |
| WO-2001092288-A2 | COBALAMIN COMPOUNDS USEFUL AS ANTIBIOTIC AGENTS AND AS IMAGING AGENTS | MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH (US) | 2001-12-06 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090263495-A1 | BACTERIOSTATIC OR BACTERIOCIDAL COMPOSITIONS AND METHODS | MB, AQP1, LPO | KDM4E 4844/4885LMNA 2708/4885RARB 1004/4885 |
| US-20260027140-A1 | COMPOSITIONS AND METHODS FOR TREATING AND AMELIORATING RESPIRATORY CONDITIONS AND INFLAMMATION OF MUCOSA | IL1B, IL5, SERPINB1 | KDM4E 4014/4885LMNA 205/4885RARB 1137/4885 |
| US-20100009008-A1 | BACTERIOSTATIC OR BACTERIOCIDAL COMPOSITIONS AND METHODS | MB, LPO, BLK | KDM4E 4823/4885LMNA 2533/4885RARB 1404/4885 |
| US-20020042394-A1 | Cobalamin compounds useful as antibiotic agents and as imaging agents | MMAB, BLVRB, AHCY | KDM4E 4257/4885LMNA 1509/4885RARB 1012/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.